Vyant Bio, Inc.
VYNT
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 397.00K | 443.00K | 666.00K | 980.00K | 1.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 397.00K | 443.00K | 666.00K | 980.00K | 1.08M |
| Cost of Revenue | 736.00K | 764.00K | 1.01M | 1.42M | 1.63M |
| Gross Profit | -339.00K | -321.00K | -342.00K | -441.00K | -545.00K |
| SG&A Expenses | 8.49M | 9.49M | 8.80M | 9.04M | 9.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.08M | 16.79M | 16.58M | 17.02M | 16.72M |
| Operating Income | -13.68M | -16.35M | -15.91M | -16.04M | -15.64M |
| Income Before Tax | -13.03M | -15.73M | -15.81M | -16.37M | -15.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.03 | -15.73 | -15.81 | -16.37 | -15.99 |
| Earnings from Discontinued Operations | -798.00K | -2.28M | -6.88M | -26.91M | -28.28M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.83M | -18.01M | -22.69M | -43.28M | -44.28M |
| EBIT | -13.68M | -16.35M | -15.91M | -16.04M | -15.64M |
| EBITDA | -13.28M | -15.85M | -15.39M | -15.50M | -15.05M |
| EPS Basic | -2.28 | -3.01 | -3.88 | -7.44 | -7.62 |
| Normalized Basic EPS | -1.39 | -1.69 | -1.68 | -1.73 | -1.70 |
| EPS Diluted | -2.28 | -3.01 | -3.88 | -7.44 | -7.62 |
| Normalized Diluted EPS | -1.39 | -1.69 | -1.68 | -1.73 | -1.70 |
| Average Basic Shares Outstanding | 24.36M | 23.92M | 23.47M | 23.37M | 23.29M |
| Average Diluted Shares Outstanding | 24.36M | 23.92M | 23.47M | 23.37M | 23.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |